|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||455.85 - 469.00|
|52 Week Range||312.00 - 564.75|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||154.79|
|Forward Dividend & Yield||6.75 (1.48%)|
|Ex-Dividend Date||Aug 19, 2020|
|1y Target Est||567.59|
Sun Pharma Issues Voluntary Nationwide Recall of RIOMET ER (metformin hydrochloride for extended-release oral suspension)
The Indian pharma stock surge dates to April, when the ban on exporting hydroxycholoroquine was lifted. The sector's stocks jumped, but the gains won't last as U.S. scrutiny returns.
India's Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world's third worst-hit nation. Favipiravir, along with another antiviral, remdesivir, has emerged as one of the most sought-after drugs at hospitals fighting COVID-19 in India, which saw a surge of 50,000-plus infections for the sixth straight day on Tuesday. Sun's version of favipiravir, to be called FluGuard, will cost 35 rupees (47 cents) per 200 mg tablet, making it the cheapest version available.